Metabasis, Merck To Advance AMPK Activator For Late Preclinical Development
Metabasis to receive one time payment of $6 million
Metabasis and its partner Merck have announced that AMP protein kinase (AMPK) activators, has yielded a lead candidate that Merck has selected to advance into late preclinical development.
Under the amended agreement, Merck has agreed to pay $6 million as one time payment to Metabasis, which satisfies all future obligations for milestones and royalty payments.
Metabasis and Merck entered into a collaboration and license agreement in June 2005. The collaboration is focused on the discovery, development and commercialization of AMPK activators for the treatment of various metabolic diseases.
As per the original agreement, Metabasis received funding for a three year research term, which was extended by another year, through June 2009. Also, Metabasis received an upfront payment of $5 million funding for its research contribution to the program. Also, the company was eligible to receive payments upon achievement of certain milestones associated with the development of a product candidate, as well as a royalty on net sales should a product be commercialized.
Related Insight
Suppliers Directory
Biospectra - High Purity Biological Buffers
Biospectra manufactures high purity biological buffers specifically intended for use in biopharm applications.
Suppliers
Capsugel - Providing Innovative Dosage Forms and Solutions to Health Care Customers
Capsugel is committed to be the leading provider of innovative dosage forms and solutions to healthcare customers around the world.
Suppliers
CCL Label - Global Healthcare and Pharmaceutical Packaging Solutions
CCL Label is a Global Manufacturer of Pharmaceutical and Healthcare packaging. With 19 healthcare sites globally, we offer the expertise, trained personnel and dedicated production capabilities to ensure that your pharmaceutical/healthcare labelling is accurate, secure and meets all FDA requirements and current Good Manufacturing Practices (GMP)
Suppliers
PharmARC - Analytic Solutions for Efficient Commercialisation of Drugs and Medical Products
PharmARC is a 100% life sciences focused company that provides analytic solutions for efficient commercialization of drugs and medical products. We enable our customers to make informed decisions related to their sales and marketing strategies, and implementation, yielding better ROI.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Introducing the miVac Range
Published by Genevac
White Papers
Reduced Solvent Consumption and Operational Costs with Existing LC Systems
Published by Shimadzu PBR
White Papers
Oncology Imaging
Published by CoreLab Partners
White Papers
Farfield Analight 4D Workstation
Published by Farfield Group
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.